Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia
- Sponsor
- Chinese PLA General Hospital
- Study ID
- NCT07612605
- Phase
- EARLY_PHASE1
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Pneumonia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- YHDF placebo — DRUG7-14 days treatment with YHDF placebo
- Bacteriophage Placebo — DRUG7-14 days treatment with bacteriophage placebo
- YHDF Drug — DRUG7-14 days treatment with YHDF
- Bacteriophage — DRUG7-14 days treatment with bacteriophage
Study Details
Through a prospective randomized controlled trial, we systematically evaluate the effects of Yiqi Huoxue Jiedu Formula combined with bacteriophage therapy on the bacterial clearance rate, disease improvement rate and mortality rate in patients with severe pneumonia caused by drug-resistant bacteria, so as to clarify its clinical transformation value.
Key Dates
- First listed
- May 29, 2026
- Start date
- Jun 1, 2026
- Status verified
- May 2026
- Primary completion
- Dec 31, 2028
- Completion
- Dec 31, 2029
Study Design
- Enrollment
- 250 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: YHDF Placebo + Bacteriophage Placebo Group7-14 days treatment with YHDF placebo, 7-14 days treatment with phage placebo
- Active Comparator: YHDF Placebo + Bacteriophage Group7-14 days treatment with YHDF placebo, 7-14 days treatment with phage placebo
- Active Comparator: YHDF Drug + Bacteriophage Placebo Group7-14 days treatment with YHDF, 7-14 days treatment with phage placebo
- Active Comparator: YHDF Drug + Bacteriophage Group7-14 days treatment with YHDF, 7-14 days treatment with phage
Primary Outcome Measure
Clearance rate of drug-resistant bacteria [ Time Frame: 14 days ]
Central Contacts
- Jianqiao Xu8617310692712
- Congyang Zheng8618323063716
Related Studies
- Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Study of Lung Proteins in Patients With PneumoniaRecruiting · National Institutes of Health Clinical Center (CC) · Bethesda, Maryland
- The Role of Circadian Clock Proteins in Innate and Adaptive ImmunityRecruiting · Washington University School of Medicine · St Louis, Missouri
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Recruiting · Duke University · Little Rock, Arkansas